Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Clin Cancer Res OF1–OF11.

https://doi.org/10.1158/1078-0432.CCR-24-0439

Published: 07 January 2025

View article titled, Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Includes: Supplementary data

Journal Articles

Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing

Clin Cancer Res (2024) 30 (17): 3957.

https://doi.org/10.1158/1078-0432.CCR-24-2131

Published: 03 September 2024

View article titled, Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Journal Articles

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Clin Cancer Res (2023) 29 (1): 67–80.

https://doi.org/10.1158/1078-0432.CCR-22-1281

Published: 04 January 2023

View article titled, Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Includes: Supplementary data

Journal Articles

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, Matteo Duca, Giuseppe Curigliano, Armando Santoro, Takafumi Koyama, Michelle Brown, Heather Vezina, Chunsheng He, Quincy Siu-Chung Chu

Clin Cancer Res (2022) 28 (1): 95–105.

https://doi.org/10.1158/1078-0432.CCR-21-1181

Published: 01 January 2022

View article titled, Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, Sara Cresta, Rachel M. Layman, Francois P. Duhoux, Catherine Terret, Shunji Takahashi, Jens Huober, Nicole Kundamal, Qing Sheng, Alejandro Balbin, Yan Ji, Wei He, Adam Crystal, Serena De Vita, Giuseppe Curigliano

Clin Cancer Res (2021) 27 (21): 5760–5770.

https://doi.org/10.1158/1078-0432.CCR-21-1095

Published: 01 November 2021

View article titled, A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Includes: Supplementary data

Journal Articles

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing

Clin Cancer Res (2021) 27 (13): 3620–3629.

https://doi.org/10.1158/1078-0432.CCR-20-4746

Published: 01 July 2021

View article titled, Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Clin Cancer Res (2021) 27 (12): 3443–3455.

https://doi.org/10.1158/1078-0432.CCR-20-4928

Published: 15 June 2021

View article titled, Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Includes: Supplementary data

Journal Articles

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Clin Cancer Res (2021) 27 (2): 438–446.

https://doi.org/10.1158/1078-0432.CCR-20-2380

Published: 19 January 2021

View article titled, Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Includes: Supplementary data

Journal Articles

Progresses Toward Precision Medicine in RET-altered Solid Tumors

Carmen Belli, Santosh Anand, Justin F. Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano

Clin Cancer Res (2020) 26 (23): 6102–6111.

https://doi.org/10.1158/1078-0432.CCR-20-1587

Published: 01 December 2020

View article titled, Progresses Toward Precision Medicine in RET-altered Solid Tumors

Journal Articles

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo, Luca Malorni

Clin Cancer Res (2020) 26 (9): 2131–2139.

https://doi.org/10.1158/1078-0432.CCR-19-3271

Published: 01 May 2020

View article titled, Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Includes: Supplementary data

Journal Articles

Lucitanib for the Treatment of HR⁺/HER2⁻ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Clin Cancer Res (2020) 26 (2): 354–363.

https://doi.org/10.1158/1078-0432.CCR-19-1164

Published: 15 January 2020

View article titled, Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Includes: Supplementary data

Journal Articles

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Giuseppe Curigliano, Carmen Criscitiello, Lucia Gelao, Aron Goldhirsch

Clin Cancer Res (2013) 19 (20): 5564–5571.

https://doi.org/10.1158/1078-0432.CCR-12-3697

Published: 14 October 2013

View article titled, Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Journal Articles

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

Fabrice Andre, Maria V. Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi

Clin Cancer Res (2013) 19 (1): 28–33.

https://doi.org/10.1158/1078-0432.CCR-11-2701

Published: 02 January 2013

View article titled, Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

Journal Articles

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste Gentilini, Paolo Veronesi, Richard D. Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini, Mattia Intra, Viviana Galimberti, Giuseppe Renne, Franco Nolè, Giulia Peruzzotti, Aron Goldhirsch

Clin Cancer Res (2004) 10 (19): 6622–6628.

https://doi.org/10.1158/1078-0432.CCR-04-0380

Published: 08 October 2004

View article titled, Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: <subtitle>A Study of Preoperative Treatment</subtitle>

Journal Articles

Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer

Gianluigi Ferretti, Giuseppe Curigliano, Ugo Pastorino, Achille Cittadini, Giovanna Flamini, Maria Grazia Calabrò, Tommaso De Pas, Laura Orlando, Mario Mandalà, Marco Colleoni, Lorenzo Spaggiari, Pier Luigi Granone, Gabriella Pagliari, Filippo de Braud, Nicola Fazio, Aron Goldhirsch

Clin Cancer Res (2000) 6 (6): 2393–2400.

Published: 01 June 2000

View article titled, Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer

NARROW

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Progresses Toward Precision Medicine in RET-altered Solid Tumors

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Lucitanib for the Treatment of HR⁺/HER2⁻ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only